Filing summary
Important identification mismatch: The request identifies Riot Platforms, Inc. and “2012 Q4,” but the supplied filing is Venaxis, Inc.’s Form 10-K for the fiscal year ended December 31, 2012. It does not provide Riot Platforms financial or operating information. The summary below describes only the supplied Venaxis filing.
Business context and reporting period
Venaxis, formerly AspenBio Pharma, Inc., was developing APPY1, a blood-based test intended to help clinicians assess appendicitis risk in patients ages 2–20. The company had largely wound down its former human-antigen business and, in July 2012, licensed its animal-health assets to a third party. The company changed its name to Venaxis in December 2012.
The filing reports the year ended December 31, 2012, with comparisons to 2011 and 2010. The financial statements received an unmodified independent auditor’s opinion.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Total revenue | $62,128 | $281,599 |
| Net loss | $9.21 million | $10.21 million |
| Operating loss | $8.96 million | $10.98 million |
| Operating expenses | $9.02 million | $11.24 million |
| Cash used in operating activities | $5.49 million | $8.33 million |
| Cash, cash equivalents and short-term investments at year-end | $12.14 million | $3.97 million |
| Working capital at year-end | $8.45 million | Not stated in the cited discussion |
| Total liabilities at year-end | $5.92 million | $4.90 million |
| Stockholders’ equity at year-end | $10.69 million | $3.83 million |
Revenue comprised $41,557 in product sales and $20,571 in animal-health license-fee revenue. Product sales fell 81% from 2011 as the company continued to wind down antigen production. Gross profit was $40,965, about 66% of total revenue; the filing reports product-sales gross profit margins of 99% in 2012 and 93% in 2011. No meaningful operating margin is indicated given continuing operating losses.
R&D expense declined 32% to $3.84 million, and selling, general and administrative expense declined 7% to $5.18 million. The 2012 net loss improved from 2011, but 2011 included a $938,896 gain from termination of the Novartis animal-health agreement. Cash from financing was $13.81 million, mainly from public stock offerings; net cash increased by $8.01 million during 2012.
Debt and other obligations totaled approximately $3.05 million at year-end, including a $2.44 million mortgage and a $398,000 Novartis termination obligation. Approximately $2.29 million of debt obligations were classified as current. A roughly $1.6 million mortgage balloon payment was due in July 2013; the company was seeking to refinance it.
Changes, outlook and key risks
- Two 2012 public offerings generated $15.15 million in net proceeds, substantially increasing year-end cash, but also increasing shares outstanding. The company had 9,954,380 shares outstanding at March 20, 2013.
- APPY1’s 2011 pilot study reported 96% sensitivity, 97% negative predictive value and 43% specificity. These were pilot results, not pivotal-trial results. The pivotal U.S. trial began enrolling in January 2013; management expected enrollment to take six to eight months and planned to seek FDA clearance subject to results.
- CE marking for APPY1 was obtained in January 2013. European commercialization was at an early stage; a February 2013 Benelux development agreement included an initial stocking order.
- Management expected 2013 R&D spending to increase, principally because of an anticipated U.S. clinical trial of approximately 2,000 evaluable patients. Capital expenditures for 2013 were estimated at $75,000–$125,000.
- Management believed existing working capital would cover estimated needs through the remainder of 2013 and at least into 2014, while also stating that additional financing was being pursued and was not assured. Without additional capital, the company could reduce R&D or cease operations. The filing notes recurring losses and negative operating cash flows.
- Potential animal-health license receipts included $408,000 in license fees, up to $1.1 million in milestones, potentially another $2 million for additional products, and royalties; these amounts depended on future payments, milestones, development, approvals and sales.
- Risks include FDA clearance and clinical-trial uncertainty, commercialization and reimbursement, financing and dilution, manufacturing and supplier execution, intellectual-property protection, and dependence on key personnel. A securities class-action dismissal was under appeal; a related derivative action was administratively closed pending the appeal. The Chipman action was dismissed without appeal.
- The company reported effective disclosure controls and internal control over financial reporting as of December 31, 2012.
Important facts for investors to verify
- Confirm the intended issuer and filing: the supplied document is Venaxis, Inc., not Riot Platforms, Inc.
- Check subsequent filings for the APPY1 pivotal-trial enrollment, results and FDA submission or clearance, and for the European launch’s commercial progress.
- Verify the outcome of refinancing or repayment of the July 2013 mortgage balloon and the company’s subsequent liquidity and financing needs.
- Assess actual receipts from the animal-health license, including fees, milestones and royalties, rather than treating contingent amounts as assured revenue.
- Review the appellate and derivative-litigation status and any subsequent developments affecting the company’s financial position.